MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Pancreas, Pancreatic
Immuneering Corporation (NASDAQ: IMRX)*
Organization & Developments: Immuneering Corp
Parents
Immuneering Corporation (NASDAQ: IMRX)*
Children
*Early stage programs include six novel drug programs for patients with solid tumors and two that seek to bring precision medicine to patients with Alzheimer’s disease.
*Immuneering’s lead product candidate IMM-1-104 aims to achieve pan-KRAS/NRAS activity while sparing normal healthy cells by driving deep cyclic inhibition of the MAPK pathway.
2024: Immuneering Corporation (IMRX) Granted Orphan Drug Designation for IMM-1-104
2024: Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone
2025: Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
Jumps
Finance & Acquisitions: Immuneering Corp
Key People: Immuneering Corp